Company intelligence / Profile preview

Buckle Therapeutics

Cambridge, Massachusetts, United Statesbuckletherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has dosed its first patient in a Phase 1 clinical trial with CLSP‑1025—a first-in-class T-cell engager targeting the p53 R175H mutation. Preclinical data show potent anti-tumor activity and high selectivity/safety profile. The approach aims to overcome limitations of current TCEs by achieving absolute tumor specificity and minimizing off-target toxicity.

Additional preclinical programs are expected as more driver mutations are identified.

Therapeutic areas: Oncology
Modalities: T cell engagers (TCEs)Protein-based biologics (pHLAre™ molecules)
Industry: Biotech

Drug pipeline

1 asset

naloxone

Pre-clinical

Indications: Opioid overdose

Beyond the preview

Go deeper on Buckle Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buckle Therapeutics.

Explore the full profile